Oxford Biomedica Solutions
Melissa P. has an extensive work experience spanning from 2014 to the present. Melissa most recently worked at Oxford Biomedica Solutions as the Director of Finance, Accounting, and Financial Reporting since September 2022. Prior to that, they held roles at Homology Medicines, Inc., including Director, Assistant Controller from February 2022 to September 2022, Associate Director of Finance from March 2020 to February 2022, and Accounting Manager from June 2018 to March 2020. Before joining Homology Medicines, Inc., Melissa worked at Pure Barre Burlington as an Instructor from April 2014 to January 2020. Melissa also gained experience at Flexion Therapeutics where they served as Manager, General Accounting from July 2017 to June 2018 and as a Senior Accountant from June 2014 to July 2017.
Melissa P. completed their Bachelor's degree in Liberal Arts and Sciences/Liberal Studies at UMass Boston from 2002 to 2004. Following this, they pursued a Master of Business Administration (MBA) with a focus on Accounting and Finance at Endicott College from 2016 to 2018.
This person is not in any offices
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.